Shares of GlaxoSmithKline plc (LON:GSK) traded down 0% on Tuesday . The company traded as low as GBX 1,343 ($18.21) and last traded at GBX 1,346.80 ($18.26). 8,370,000 shares changed hands during trading, a decline of 4% from the average session volume of 8,680,000 shares. The stock had previously closed at GBX 1,346.80 ($18.26).
A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. set a GBX 1,340 ($18.17) target price on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a report on Thursday, January 4th. Berenberg Bank reissued a “buy” rating and issued a GBX 1,760 ($23.87) price target on shares of GlaxoSmithKline in a report on Wednesday, December 13th. UBS Group set a GBX 1,550 ($21.02) price target on shares of GlaxoSmithKline and gave the stock a “buy” rating in a report on Wednesday, December 13th. Citigroup reissued a “neutral” rating and issued a GBX 1,400 ($18.99) price target on shares of GlaxoSmithKline in a report on Wednesday, December 13th. Finally, Bank of America set a GBX 1,450 ($19.66) price target on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a report on Wednesday, December 6th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of GBX 1,563.33 ($21.20).
The company has a market cap of $66,770.00 and a PE ratio of 2,805.83.
The business also recently announced a dividend, which will be paid on Thursday, January 11th. Stockholders of record on Thursday, November 9th will be given a GBX 19 ($0.26) dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a dividend yield of 1.41%.
In other GlaxoSmithKline news, insider Simon Dingemans purchased 1,076 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The stock was bought at an average cost of GBX 1,527 ($20.71) per share, for a total transaction of £16,430.52 ($22,281.69). Also, insider Patrick Vallance sold 20,000 shares of the stock in a transaction dated Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($17.77), for a total transaction of £262,000 ($355,302.41). Over the last ninety days, insiders bought 1,568 shares of company stock valued at $2,386,424.
ILLEGAL ACTIVITY WARNING: This report was first reported by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://baseballnewssource.com/markets/glaxosmithkline-gsk-stock-price-down-0/1821196.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.